TY - JOUR
T1 - Analgesic effects of nefopam in patients undergoing bimaxillary osteotomy
T2 - A double-blind, randomized, placebo-controlled study
AU - Park, Hue Jung
AU - Park, Je Uk
AU - Yoo, Woojoo
AU - Moon, Young Eun
N1 - Publisher Copyright:
© 2015 European Association for Cranio-Maxillo-Facial Surgery.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Purpose Many studies have examined the postoperative analgesic effects of nefopam in various settings. However, although nefopam is expected to be useful in bimaxillary osteotomy, no published data are available. Material and methods We divided 42 patients into nefopam [n = 21, nefopam 20 mg intravenous (i.v.) 30 min before surgery, followed by an i.v. infusion (5 mg/h) beginning immediately postoperatively for 24 h] and control [n = 21, normal saline] groups. Then we compared the analgesic efficacy, side effects, and degree of patient satisfaction with postoperative analgesia. Results Pain was lower in the nefopam group than in the controls in the recovery room [4.6 (3.0-6.0) vs. 6.0 (5.5-7.0), median (interquartile range), P = 0.002] and on the ward. Fewer patients in the nefopam group required rescue analgesics, and the degree of patient satisfaction was significantly higher in the nefopam group (P < 0.001). There were no significant differences in other side effects between the groups. However, the control group showed more sedation 1 h postoperatively (P = 0.009). Conclusion Nefopam is an effective analgesic in bimaxillary osteotomy in that it can reduce the use of opioids and nonsteroidal anti-inflammatory drugs, thereby reducing the side effects of conventional analgesics. (Trial Registration: ClinicalTrials.gov
AB - Purpose Many studies have examined the postoperative analgesic effects of nefopam in various settings. However, although nefopam is expected to be useful in bimaxillary osteotomy, no published data are available. Material and methods We divided 42 patients into nefopam [n = 21, nefopam 20 mg intravenous (i.v.) 30 min before surgery, followed by an i.v. infusion (5 mg/h) beginning immediately postoperatively for 24 h] and control [n = 21, normal saline] groups. Then we compared the analgesic efficacy, side effects, and degree of patient satisfaction with postoperative analgesia. Results Pain was lower in the nefopam group than in the controls in the recovery room [4.6 (3.0-6.0) vs. 6.0 (5.5-7.0), median (interquartile range), P = 0.002] and on the ward. Fewer patients in the nefopam group required rescue analgesics, and the degree of patient satisfaction was significantly higher in the nefopam group (P < 0.001). There were no significant differences in other side effects between the groups. However, the control group showed more sedation 1 h postoperatively (P = 0.009). Conclusion Nefopam is an effective analgesic in bimaxillary osteotomy in that it can reduce the use of opioids and nonsteroidal anti-inflammatory drugs, thereby reducing the side effects of conventional analgesics. (Trial Registration: ClinicalTrials.gov
KW - Bimaxillary osteotomy
KW - NSAIDs
KW - Nefopam
KW - Opioid
KW - Sedation
UR - http://www.scopus.com/inward/record.url?scp=84956643394&partnerID=8YFLogxK
U2 - 10.1016/j.jcms.2015.11.012
DO - 10.1016/j.jcms.2015.11.012
M3 - Article
C2 - 26725583
AN - SCOPUS:84956643394
SN - 1010-5182
VL - 44
SP - 210
EP - 214
JO - Journal of Cranio-Maxillofacial Surgery
JF - Journal of Cranio-Maxillofacial Surgery
IS - 2
ER -